ONCAlert | 2018 ASCO Annual Meeting

Combination of Veliparib and Chemotherapy in BRCA-Positive Breast Cancer

Hyo Sook Han, MD
Published Online: 1:59 PM, Sat December 10, 2016

Hyo Sook Han, MD, medical oncologist, Moffitt Cancer Center, discusses results of the phase II BROCADE trial, which evaluated the combination of the PARP inhibitor veliparib with carboplatin/paclitaxel in patients with BRCA-positive breast cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.